首页> 外文期刊>Archives of Internal Medicine >Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.
【24h】

Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.

机译:糖皮质激素使用和房颤的风险或颤振:以人群为基础的病例对照研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Glucocorticoid use is associated with increased risk of myocardial infarction, stroke, and heart failure, but data are limited on the risk of atrial fibrillation or flutter. We examined whether glucocorticoid use is associated with the risk of atrial fibrillation or flutter. METHODS: For this population-based, case-control study, we identified all patients with a first hospital diagnosis of atrial fibrillation or flutter from January 1, 1999, through December 31, 2005, in Northern Denmark (population, 1.7 million). For each case we selected 10 population controls matched by age and sex. We obtained data on glucocorticoid prescriptions within 60 days (current users) or longer before the index date (former users), comorbidity, and medications from medical databases. We used conditional logistic regression to compute odds ratios (ORs), controlling for potential confounders. RESULTS: Among 20,221 patients with atrial fibrillation or flutter, 1288 (6.4%) were current glucocorticoid users and 2375 (11.7%) were former users. Among 202,130 population controls, 5245 (2.6%) were current glucocorticoid users and 19 940 (9.9%) were former users. Current glucocorticoid use was associated with an increased risk of atrial fibrillation or flutter compared with never use (adjusted OR, 1.92; 95% confidence interval [CI], 1.79-2.06). Among new glucocorticoid users, the adjusted OR was 3.62 (95% CI, 3.11-4.22) and among long-term users it was 1.66 (95% CI, 1.53-1.80). The increased risk remained robust in patients with and without pulmonary and cardiovascular diseases. Former glucocorticoid use was not associated with increased risk (adjusted OR, 1.00; 95% CI, 0.96-1.06). CONCLUSION: Current glucocorticoid use was associated with an almost 2-fold increased risk of atrial fibrillation or flutter.
机译:背景:糖皮质激素使用有关心肌梗死,中风的风险增加,和心力衰竭,但数据是有限的心房颤动或扑动的风险。检查是否有关糖皮质激素使用房颤的风险或颤动。方法:对这个人群为基础的病例对照研究中,我们发现所有的病人医院诊断为房颤或颤振从1999年1月1日至12月31日,2005年,在丹麦北部(人口,1.7百万)。控制年龄和性别相匹配。在60天内糖皮质激素的处方(当前用户)索引日期之前或更长时间(前用户)、疾病和药物医学数据库。回归计算优势比(ORs),控制了潜在的混杂因素。在20221例心房纤颤或颤振,1288(6.4%)目前糖皮质激素前用户用户和2375年(11.7%)。202130人口控制,5245 (2.6%)目前糖皮质激素用户和19 940 (9.9%)前用户。与心房的风险增加有关纤维性颤动或颤动而从不使用(调整或,1.92;1.79 - -2.06)。调整或为3.62 (95% CI, 3.11 - -4.22)在长期的用户是1.66(95%可信区间,1.53 - -1.80)。患者和没有肺心血管疾病。使用与风险增加无关(调整或,1.00;结论:糖皮质激素使用与几乎的高风险有关心房纤颤或颤动。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号